Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20527288 | 0.94 | NR3C1 (0.36) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL19026268 | 0.93 | CA12 (0.37) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL18019443 | 0.92 | NR3C1 (0.37) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL23910524 | 0.92 | NR3C1 (0.38) | NR3C1HTTFNTAFNTBSMN1; SMN2 | |
| SCHEMBL16945805 | 0.92 | NR3C1 (0.38) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL23846023 | 0.91 | NR3C1 (0.38) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL23961616 | 0.91 | NR3C1 (0.38) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL24898123 | 0.91 | NR3C1 (0.38) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL22482987 | 0.90 | NR3C1 (0.36) | NR3C1CA12CA1CA2CA4 | |
| SCHEMBL27432928 | 0.90 | NR3C1 (0.36) | NR3C1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | claimed |
| US-20180339985-A1 | PDD COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2018-11-29 | — | — | US | claimed |
| US-20180291021-A1 | PDD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-10-11 | — | — | US | claimed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| WO-2024013724-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024013723-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | disclosed |
| EP-3938372-B1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| US-20230143309-A1 | PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-11517626-B2 | Pyrrolobenzodiazepine antibody conjugates | MEDIMMUNE LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| EP-3612537-B1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LTD (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3191490-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2019-08-07 | — | — | EP | disclosed |
| US-10350218-B2 | Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers | CELLERANT THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10188746-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| EP-3413923-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | Medimmune Limited (GB) | 2018-12-19 | — | — | EP | disclosed |
| US-20180177795-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | CELLERANT THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20170340752-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-11-30 | — | — | US | disclosed |
| US-20170239365-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| WO-2017137553-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUME LIMITED (GB) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017137556-A1 | PYRROLOBENZODIAZEPINE ANTI-HER2 ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177795-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | BCL6B, HTR2B, IDO1 | NR3C1 3876/4885CA12 772/4885CA1 1239/4885 |
| US-20180291021-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | NR3C1 95/4885CA12 2777/4885CA1 2488/4885 |
| US-20170239365-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, BOD1L1, GABRA1 | NR3C1 1157/4885CA12 2228/4885CA1 718/4885 |
| US-20230143309-A1 | PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES | CD79B, H1-10, DRD1 | NR3C1 2091/4885CA12 312/4885CA1 620/4885 |
| US-10188746-B2 | Pyrrolobenzodiazepines and conjugates thereof | CD22, GABRA1, CCNB1 | NR3C1 1838/4885CA12 362/4885CA1 408/4885 |
| US-10350218-B2 | Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers | BCL6B, HTR2B, IDO1 | NR3C1 3876/4885CA12 772/4885CA1 1239/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | NR3C1 2940/4885CA12 150/4885CA1 1063/4885 |
| US-11517626-B2 | Pyrrolobenzodiazepine antibody conjugates | CD79B, DRD1, H1-10 | NR3C1 1780/4885CA12 471/4885CA1 551/4885 |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | MKI67, CCND2, CCND1 | NR3C1 857/4885CA12 4681/4885CA1 4493/4885 |
| US-20180339985-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | NR3C1 251/4885CA12 2551/4885CA1 1841/4885 |
| US-20170340752-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD22, GABRA1, CCNB1 | NR3C1 1838/4885CA12 362/4885CA1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.